Prime Medicine (PRME) Enterprise Value (2021 - 2026)
Prime Medicine's (PRME) quarterly Enterprise Value came in at -$135.5 million in Q1 2026, down 41.45% YoY from -$231.4 million in Q1 2025, and up 23.74% on a QoQ basis from -$177.7 million in Q4 2025.
Prime Medicine (PRME) Enterprise Value (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Enterprise Value data on file, last reported at -$135.5 million in Q1 2026.
- Quarterly Enterprise Value fell 41.45% year-over-year to -$135.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135.5 million (down 41.45% YoY) and the FY2025 annual result came in at -$177.7 million, up 4.2% from the prior year.
- Enterprise Value advanced to -$135.5 million in Q1 2026, from -$177.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$47.0 million in Q4 2023 to a low of -$286.1 million in Q4 2022.
- A 5-year average of -$132.7 million and a median of -$127.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 83.56% — and 2024, when it plunged 294.41%.
- Tracing PRME's Enterprise Value over 5 years: stood at -$286.1 million in 2022, then soared by 83.56% to -$47.0 million in 2023, then sank by 294.41% to -$185.5 million in 2024, then climbed by 4.2% to -$177.7 million in 2025, then climbed by 23.74% to -$135.5 million in 2026.
- The last three Enterprise Value figures came in at -$135.5 million (Q1 2026), -$177.7 million (Q4 2025), and -$76.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -95.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.07 Mn |
| Mar 31, 2026 | -135.50 Mn |
| Dec 31, 2025 | -177.68 Mn |
| Sep 30, 2025 | -76.26 Mn |
| Jun 30, 2025 | -57.21 Mn |
| Mar 31, 2025 | -95.79 Mn |
| Dec 31, 2024 | -185.47 Mn |
| Sep 30, 2024 | -122.89 Mn |
| Jun 30, 2024 | -158.18 Mn |
| Mar 31, 2024 | -100.78 Mn |
| Dec 31, 2023 | -47.03 Mn |
| Sep 30, 2023 | -48.78 Mn |
| Jun 30, 2023 | -126.97 Mn |
| Mar 31, 2023 | -243.39 Mn |
| Dec 31, 2022 | -286.09 Mn |
| Sep 30, 2022 | -137.12 Mn |
| Jun 30, 2022 | -92.24 Mn |
| Mar 31, 2022 | -164.25 Mn |
| Dec 31, 2021 | -117.74 Mn |
| Sep 30, 2021 | -200.66 Mn |